Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology, announced that Wei Fu, the Chairman of the Board, plans to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) in open market transactions. These purchases will be executed via his controlled entity, although the exact number of ADSs and the timeframe for acquisition remain uncertain.
Wei Fu stated that the Board and senior leadership successfully executed the corporate strategy for 2024, aligning with the long-term goal of increasing shareholder value. The company recently prioritized its portfolio, designating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, as its lead clinical program. Data from a dose escalation study combining givastomig with nivolumab and chemotherapy are expected in early H2 2025, with a 40-patient dose expansion study data anticipated in early 2026.
The company's current cash runway extends into 2027.
I-Mab (NASDAQ: IMAB) has announced a strategic portfolio prioritization focusing on givastomig, its lead clinical program targeting first-line metastatic gastric cancers. The company has completed enrollment for a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, with data expected in early H2 2025.
A 40-patient dose expansion study is ongoing with results anticipated in early 2026. The company's cash balance of $184.4 million (as of September 30, 2024) is expected to support operations into 2027.
Phase 1 trials showed an overall response rate of 16.3% (7/43) for givastomig monotherapy, with favorable safety profiles. The company is pausing the development of uliledlimab to focus resources on givastomig, while maintaining its partnership with ABL Bio for ragistomig development.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024. The company's management team will deliver a presentation on December 4 at 4:30 p.m. ET. Key participants include CEO Sean Fu, CMO Phillip Dennis, CFO Joseph Skelton, and Senior Director of IR Tyler Ehler. The event will feature one-on-one and small group meetings during December 3-4. A webcast of the presentation will be accessible through the company's IR website.
I-Mab (NASDAQ: IMAB) reported Q3 2024 financial results and pipeline updates. The company ended Q3 with $184.4 million in cash and equivalents, expecting runway into 2027. Key developments include the appointment of Dr. Sean Fu as permanent CEO and encouraging clinical data for givastomig presented at ESMO 2024. The company reported a net loss from continuing operations of $20.5 million for Q3 2024. R&D expenses were $4.5 million, down from $5.1 million in Q3 2023. The company is preparing for a Phase 2 study of uliledlimab in first-line mNSCLC, with first patient dosing expected in 1H 2025.
I-Mab (NASDAQ: IMAB) has appointed Sean Fu, PhD, MBA as permanent Chief Executive Officer effective November 1, 2024, following his interim CEO role since July 15, 2024. Dr. Fu brings over 20 years of life sciences industry experience, including roles as Operating Partner at ABio-X, co-founder and CEO of RVAC Medicines, and Group VP at Luye Pharma Group. He previously spent 15 years at Merck & Co., managing late-stage clinical portfolio finances and leading R&D network integration following the $42 billion Merck-Schering-Plough merger. Dr. Fu holds a PhD from Ohio State University and an MBA from Wharton.
I-Mab (NASDAQ: IMAB) announced it will release its Q3 2024 financial results on November 14, 2024, before the US market opens. The company will not hold a conference call for Q3 results but plans to host an investor update call with its full-year 2024 results, where it will discuss its clinical pipeline, corporate strategy, and objectives. Financial results and related information will be available on the company's website.
I-Mab (NASDAQ: IMAB) announced it will present Phase 1 optimized dose estimation data for givastomig (TJ033721/ABL111) at SITC 2024. The presentation focuses on this novel first-in-class Claudin18.2 and 4-1BB bispecific antibody for cancer treatment. The poster presentation, numbered 1474, will take place on November 9, 2024, at the George R. Brown Convention Center in Houston, Texas, during the Society for Immunotherapy of Cancer conference. The poster details optimal dose estimation using an integrated approach from Phase 1 data and will be available on I-Mab's website under the 'Innovation, Publications & Presentations' section.
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on cancer immunotherapies, has announced its participation in the Truist Securities BioPharma Symposium on November 7, 2024. The company's management team, including Interim CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, and Senior Director of Investor Relations Tyler Ehler, will engage in one-on-one and small group meetings with investors during the event.
I-Mab (NASDAQ: IMAB) presented updated Phase 1 data for givastomig, a novel Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, at ESMO 2024. The study showed promising single-agent activity in heavily pre-treated gastric cancer patients with varying Claudin 18.2 expression levels. Key findings include:
- Recommended Phase 2 dose: 8-12 mg/kg
- Well-tolerated up to highest study doses
- Objective response rate (ORR): 16.3% (7/43 patients)
- Disease control rate (DCR): 48.8% (21/43 patients)
- No dose-limiting toxicity up to 15 mg/kg Q2W and 18 mg/kg Q3W
- Linear pharmacokinetics at doses ≥5 mg/kg
A Phase 1b study combining givastomig with standard-of-care treatment in front-line gastric cancer patients is ongoing, with results expected in H2 2025.
I-Mab (NASDAQ: IMAB) presented positive pharmacokinetics data for uliledlimab, a CD73-targeting antibody, at the 2024 World Conference on Lung Cancer. The data, derived from three Phase 1 studies, supports dosing strategies for upcoming clinical trials. Key findings include:
- 95% of the simulated population achieved target threshold with 30 mg/kg of uliledlimab
- Positive correlation between uliledlimab concentration and overall response rate probability in mNSCLC patients
- CD73 receptor occupancy in peripheral B cells reached and maintained at 90% or above
- 30 mg/kg dose with a single boost on C1D8 maintained target concentration of 80 μg/mL
A randomized Phase 2 study of uliledlimab combined with pembrolizumab and chemotherapy is expected to begin in 1H 2025.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
